ER-Positive and Triple-Negative Breast Cancer | Expert Second Opinion: Investigators Discuss Available Clinical Research in the Care of Patients with Challenging Cases of ER-Positive and Triple-Negative Breast Cancer

published 1 week ago by Dr Neil Love

Featuring perspectives from Drs Matthew P Goetz, Hope S Rugo and Melinda Telli, including the following topics: Introduction (0:00) Evolving Clinical Decision-Making for Patients with ER-Positive, HER2-Negative Localized Breast Cancer (7:33) Case: A postmenopausal woman in her mid-50s with ER-positive, PR-negative, HER2-negative pT1cN1 breast cancer — Ruth O’Regan, MD (12:57) Case: A woman in her early 40s with 6-cm ER-positive, HER2-negative localized breast cancer — Reshma Mahtani, DO (15:10) Selection and Sequence of Therapy for ER-Positive, HER2-Negative Metastatic Breast Cancer (mBC) (34:44) Case: A woman in her mid-50s with ER-positive, PR-negative, HER2-negative mBC — Dr O’Regan (36:33) Case: A woman in her early 50s with ER-positive, HER2-negative mBC — Germline BRCA2 mutation — Dr Mahtani (41:58) Case: A woman in her late 30s with ER-positive, HER2-negative mBC — Germline BRCA1 mutation — Ann Partridge, MD, MPH (46:45) New Directions in the Treatment of Triple-Negative Breast Cancer (TNBC) (53:24) Case: A woman in her early 50s with metastatic TNBC — PD-L1-positive — Dr Partridge (55:50) CME information and select publications

more episodes from Research To Practice | Oncology Videos